Sexual Dysfunction Associated with the Treatment of Depression: A Placebo-Controlled Comparison of Bupropion Sustained Release and Sertraline Treatment

References

• Settle EC: Managing antidepressant side effects. Drug Ther 1993; 23(7):17–30
   Google Scholar
• Pollack MH, Rosenbaum JF: Management of antidepressant-induced side effects: a practical guide for the clinician. J Clin Psychiatry 1987; 48:3–8
   PubMed Web of Science ®Google Scholar
• Mitchell JE, Popkin MK: Antidepressant drug therapy and sexual dysfunction in men: a review. J Clin Psychopharmacol 1983; 3:76–79
   PubMed Web of Science ®Google Scholar
• DeLeo D, Magni G: Sexual side effects of antidepressant drugs. Psychosomatics 1983; 24:1076–1082
   Google Scholar
• Herman, JB, Brotman AW, Pollack MH, Falk WE, Bieder-man J, Rosenbaum JF: Fluoxetine-induced sexual dysfunc-tion. J Clin Psychiatry 1990; 51:25–27
   PubMed Web of Science ®Google Scholar
• Segraves RT: Overview of sexual dysfunction complicating the treatment of depression. .1 Clin Psychiatry Monogr 1992; 10:4–10
   Google Scholar
• Hopkins HS: Antidotes for depression-induced sexual dys-function. Biol Ther Psychiatry 1992; 15:33–36
   Google Scholar
• Jacobsen FM: Fluoxetine-induced sexual dysfunction in an open trial of yohimbine. J Clin Psychiatry 1992; 53:119–122
   PubMed Web of Science ®Google Scholar
• Nitenson NC, Cole JO: Psychotropic-induced sexual dysfunc-tion. In: Dunner DL, ed. Current Psychiatric Therapy. Phila-delphia: Saunders; 1993:353–359
   Google Scholar
• Aizenberg D, Gur S, Zemishlany Z, Granek M, Jeczmien P, Weizman A: Mianserin, a 5-HT2e2, and a2 antagonist, in the treatment of sexual dysfunction induced by serotonin reup-take inhibitors. Clin Neuropharmacol 1997; 20(3)110–214
   Google Scholar
• Zajecka J, Fawcett J, Schaff M, Jeffriess H, Guy C: The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry 1991; 52:66–68
   PubMed Web of Science ®Google Scholar
• Sovner R: Treatment of tricyclic antidepressant-induced or-gasmic inhibition with cyproheptadine. J Clin Psychopharma-col 1984; 4:169
   PubMed Web of Science ®Google Scholar
• Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, LaPierre YD, Masco HL, Mendels 3: Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-con-trolled, multicenter comparison study in outpatients with ma-jor depression. J Clin Psychiatry 1990; 51:18–27
   PubMed Web of Science ®Google Scholar
• Cohn CK, Shrivastava R, Mendels J, Cohn JB, Fabre LR, Claghom JL, Dessain EC, Itil TM, Lautin A: Double-blind, multicenter comparison of sertraline and amitriptyline in el-derly depressed patients. J Clin Psychiatry 1990; 51:28–33
   PubMed Web of Science ®Google Scholar
• Doogan DP, Caillard V: Sertraline: a new antidepressant. J Clin Psychiatry 1988; 49\(suppl 8):46–51
   Google Scholar
• Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS: Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. I Clin Psychiatry 1996; 57\(suppl 2):53–62
   Google Scholar
• Segraves RT, Kavoussi R, Hughes AR, Batey SR, Johnston JA, Donahue R, Ascher JA: Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of bu-propion sustained release and sertraline treatment. J Clin Psychopharmacol 1999 (in press)
   Google Scholar
• Gitlin MJ: Psychotropic medications and their effects on sex-ual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994; 55:406–413
   PubMed Web of Science ®Google Scholar
• Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA: Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997; 58:532–537
   PubMed Web of Science ®Google Scholar
• Reimherr FW, Cunningham LA, Batey SR, Johnston JA, Ascher JA: A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets ver-sus placebo in depressed outpatients. Clin Ther 1998; 20:505–516
   PubMed Web of Science ®Google Scholar
• Ascher JA, Cole JO, Colin J. Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, Sulser F: Bupropion: a review of its mechanism of antidepressant activity. I Clin Psychiatry 1995; 56:395–401
   Google Scholar
• Ferris RM, Cooper BR: Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monograph 1993; 11(1):2–14
   Google Scholar
• Gardner EA, Johnston JA: Bupropion: an antidepressant without sexual pathophysiological action. J Clin Psychophar-macol 1985; 5:24–29
   PubMed Web of Science ®Google Scholar
• Modell JG, Katholi CR, Modell JD, DePalma RL: Compara-tive sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 1997; 61:476–487
   PubMed Web of Science ®Google Scholar
• Croft H, Settle E, Houser T, Batey SR, Donahue RMJ, Ascher JA: A placebo-controlled comparison of the antidepressant and sexual functioning effects of bupropion sustained release and sertraline. Clin Ther 1999; 21(4):643–658.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association: Mood Disorders. In: Diag-nostic and Statistical Manual of Mental Disorders, 4th Edition, Revised. Washington, DC: American Psychiatric Associa-tion, 1994:317–345
   Google Scholar
• Hamilton M: A rating scale for depression. J Neurol Neuro-logic Psychiatry 1960; 23:56–62
   PubMed Web of Science ®Google Scholar
• Hamilton M: Development of a rating scale for primary de-pressive illness. Br .1 Soc Clin Psychiatry 1967; 6:278–296
   PubMed Web of Science ®Google Scholar
• Graham CA, Ramos R, Bancroft J, Maglaya C, Farley TMM: The effects of steroidal contraceptives on the well-being and sexuality of women: a double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods. Contraception 1995; 52:363–369
   PubMed Web of Science ®Google Scholar
• Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 50–55
   PubMed Web of Science ®Google Scholar
• Guy W: ECDEU Assessment Manual for Psychopharmacol-ogy. US Dept. of Health, Education, and Welfare publication (ADM) 76–338. Rockville, MD: National Institute of Mental Health; 1976; 218–222
   Google Scholar
• Salazar WH: Management of depression in the outpatient office. Med Clin North Am 1996; 80(2):431–455
   Google Scholar
• McElroy SL, Keck PE, Friedman LM: Minimizing and manag-ing antidepressant side effects. J Clin Psychiatry 1995; 56\(suppl 2):49–55
   Google Scholar
• Wise TN: A model for the assessment of sexual dysfunction etiology. J Clin Psychiatry Monograph 1992; 10(2):5–18
   Google Scholar
• Sertraline (ZOLOFT®) Product Information. Pfizer Inc., 1997
   Google Scholar
• Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, MendeIs J, Petrie WM, Dube S. Small JG: Sertraline safety and efficacy in major depression: a double-blind fixed dose comparison with placebo. Biol Psychiatry 1995; 38:592–602
   Google Scholar
• Hsu JH, Shen WW: Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. Int J Psychiatry Med 1995; 25(2):191–201
   PubMed Web of Science ®Google Scholar
• Harvey KV, Baton R: Clinical implications of antidepressant drug effects on sexual function. Ann Clin Psych 1995; 7(4): 189–201
   Google Scholar
• Murdoch D, McTavish D: Sertraline: a review of its pharmaco-dynamic and pharmacokinetic properties, and therapeutic po-tential in depression and obsessive-compulsive disorder. Drugs 1992; 44:604–624
   PubMed Web of Science ®Google Scholar
• Balon R: Drug holidays to counter sexual dysfunction. Am J Psychiatry 1996; 153(10):1370–1371
   Google Scholar
• Rothschild AJ: Selective serotonin reuptake inhibitor-in-duced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry 1995; 152:1514–1516
   PubMed Web of Science ®Google Scholar
• Zajecka J, Tracy K, Mitchell S: Discontinuation symptoms following treatment with serotonin reuptake inhibitors; a liter-ature review. J Clin Psychiatry 1997; 58(7):291–297
   PubMed Web of Science ®Google Scholar